bf5f606f-17ae-46bb-b687-7863ab3d97b1
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 35
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.470
- MITOTIC_SPINDLE+0.320
- G2M_CHECKPOINT+0.310
- INTERFERON_ALPHA_RESPONSE+0.280
- CHOLESTEROL_HOMEOSTASIS+0.210
- GLYCOLYSIS+0.190
- PROTEIN_SECRETION+0.190
- APICAL_SURFACE+0.150
- INTERFERON_GAMMA_RESPONSE+0.150
- APOPTOSIS+0.130
Top 10 suppressed
- MYC_TARGETS_V2-0.570
- MYC_TARGETS_V1-0.370
- ALLOGRAFT_REJECTION-0.290
- OXIDATIVE_PHOSPHORYLATION-0.270
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.270
- INFLAMMATORY_RESPONSE-0.220
- KRAS_SIGNALING_UP-0.210
- WNT_BETA_CATENIN_SIGNALING-0.200
- PANCREAS_BETA_CELLS-0.190
- IL2_STAT5_SIGNALING-0.180
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG970 | — | — | 0.721 |
| 2 | TCGA-CR-6480-01A-11R-1873-07 | — | — | 0.679 |
| 3 | SRR650133 | — | — | 0.640 |
| 4 | MNG1076 | — | — | 0.639 |
| 5 | TCGA-D8-A1JC-01A-11R-A13Q-07 | — | B | 0.632 |
| 6 | SRR6079981 | — | — | 0.620 |
| 7 | R44 | — | — | 0.620 |
| 8 | SRR8613794 | — | C | 0.618 |
| 9 | TCGA-AR-A24N-01A-11R-A169-07 | — | B | 0.616 |
| 10 | GSM5359410 | — | — | 0.612 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.470 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.320 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.310 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.280 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.210 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.190 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.190 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.150 | Temsirolimus | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.150 | Idelalisib | — uncovered |
| APOPTOSIS | 0.130 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.130 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.120 | Temsirolimus | — uncovered |
| PEROXISOME | 0.120 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.090 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.080 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.080 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.070 | Inavolisib | — uncovered |
| HYPOXIA | 0.060 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.050 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.040 | Remibrutinib | — uncovered |